secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001193125-25-152767
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase stockholders re-elect directors, ratify auditor, approve equity plan amendment at 2025 annual meeting
--------------------------------------------------------------------------------

- Amit Munshi and David Canner re-elected as Class II directors with 56.8M and 57.7M votes for, respectively; 3.4M broker non-votes.
- CohnReznick LLP ratified as independent auditor for FY2025: 61.1M votes for, 29k against, no broker non-votes.
- Amendment to 2020 Equity Incentive Plan (evergreen provision) approved: 46.3M for, 11.4M against, 3.4M broker non-votes.
- Annual meeting held June 27, 2025; no other matters voted on.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525152767/0001193125-25-152767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525152767/d109611d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-152767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer